Introduction Emicizumab is an effective new treatment option for people with hemophilia A
(PwHA). The approved dosing regimens are based on body weight, without the necessity for …

Background Clinical trial data are scarce for the use of prophylaxis in people with non-
severe haemophilia A. The HAVEN 6 study aims to assess safety and efficacy of …

Hemophilia A, an X-linked genetic disorder, is characterized by a deficiency or dysfunction
of clotting Factor VIII. The treatment landscape has substantially changed by introducing …

Emicizumab, a bispecific monoclonal antibody, bridges activated factor IX (FIXa) and FX,
replacing the function of missing FVIIIa to restore effective hemostasis in persons with …

Background Emicizumab is a bispecific antibody that mimics the cofactor function of
activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A …

Introduction Emicizumab is a bispecific monoclonal antibody developed to address the
unmet needs of clotting factor replacement therapy and has become the benchmark for …

Background Emicizumab is a subcutaneously administered humanized, bispecific,
monoclonal antibody approved for prophylaxis in people with hemophilia A. Methods …

Many people with hemophilia A (PwHA) undergo surgery in their lifetime, often because of
complications of their disease. Emicizumab is the first bispecific monoclonal antibody …

Background Acquired haemophilia A is caused by neutralising autoantibodies against
coagulation factor VIII, leading to severe bleeding. Standard treatment involves …

Introduction Emicizumab is a humanised, bispecific monoclonal antibody mimicking the
cofactor function of activated factor (F) VIII. It is indicated for routine prophylaxis of bleeding …